Back to top

Ipsen S.A. (IPSEY) Discusses Phase II LANTIC Data and Innovation in Engineered Neuroinhibitors for Aesthetic Indications Transcript

Ipsen S.A. (IPSEY) Discusses Phase II LANTIC Data and Innovation in Engineered Neuroinhibitors for Aesthetic Indications Transcript

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

IPSEN (IPSEY)